Whole blood RNA expression profiles in ovarian cancer patients with             or without residual tumors after primary cytoreductive surgery.
Significant improvements in the treatment results of ovarian cancer have             been achieved during the last decades, but further improvements require additional             methods identifying signs of the disease and its biological behavior, preferably             by a simple blood test. We hypothesized that peripheral blood leukocytes may express             genes that carry such clinical information. Therefore, we studied the relative             gene expressions of 168 cancer- and metastasis-specific genes in blood samples             from ovarian cancer patients with different prognoses after primary cytoreductive             surgery. Total RNA was extracted from whole blood and the relative gene expression             profile of 168 genes were analyzed using real-time qPCR assays. Two groups of             patients were analyzed; one group with residual tumor mass after primary surgery,             and one group where the tumor was macroscopically radically resected, resulting             in no visible tumor mass left behind. The group with the remaining tumor mass             after surgery showed significantly different gene expression profiles compared             to the group with no remaining tumor mass. Differences were noted for the metastasis             associated 1 family, member 2 gene (MTA2), the TNF, α-catenin, interleukin 1β,             the KiSS-1 metastasis suppressor and the matrix metallo-proteinase 10 genes. All             genes were downregulated with a fold-change between 1.15 to 1.57; there were no             upregulated genes. Thus, a signature of genes involved in metastasis, invasion             and inflammation was found to be significantly downregulated in native unstimulated             blood leukocytes from ovarian cancer patients with a poor prognosis. Preoperatively             it may serve as a guide to the biology of the tumor and postoperatively in the             optimization of adjuvant treatment of ovarian cancer patients.
Department of Laboratory Medicine, Section for Clinical Chemistry, Örebro University Hospital, and Health and Medical Sciences, Örebro University, SE-701 85 Örebro, Sweden. helena.isaksson@orebroll.se
Helena S
HS
Isaksson
Bengt
B
Sorbe
Torbjörn K
TK
Nilsson
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D010166:Palliative Care; D011379:Prognosis; D012333:RNA, Messenger / Q000097:blood*; D060888:Real-Time Polymerase Chain Reaction
D012333:RNA, Messenger